Dimers or polymers
market projected to grow from $18.2B in 2025 to $72.5B by 2035 ~14.8% CAGR driven by gene editing, rare diseases, and personalized medicine At the same time, the pipeline is becoming more complex: oncology represents over 50% of CGT trials increasing focus on small, targeted patient populations These therapies introduce new operational demands: individualized treatments complex manufacturing and logistics need for more integrated trial models The implication is clear: cell and gene therapies are not scaling within traditional trial frameworks, they are forcing the industry to redesign them
It is indicated as a supportive treatment for liver disease as well as for the treatment of hepatitis, acetonuria, hypocalcaemia, paresis, milk fever, intoxication, ketosis, lumbago, tetany, puerperal diseases, and metabolic disorders
Stomach acid and intestinal enzymes break it down before meaningful quantities reach systemic circulation